Sirtex Medical (ASX:SRX) saw shares jump today after revealing plans for a major restructuring as the company looks to cut its headcount and focus on its “profitable core business.”
The company said it underwent an “extensive review of the business” to identify where it could improve efficiencies. The review led to an initial $7 million reduction in R&D in February and upcoming headcount reductions.
Read the whole story at our sister site, Drug Delivery Business